Reference : Le médicament du mois. Zoely®, une association monophasique d’estradiol et d’acétate ...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
Le médicament du mois. Zoely®, une association monophasique d’estradiol et d’acétate de nomégestrol
PINTIAUX, Axelle [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique CHR >]
Gaspard, Ulysse mailto [Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Nisolle, Michelle mailto [Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique >]
Revue Médicale de Liège
Université de Liège. Revue Médicale de Liège
Yes (verified by ORBi)
[en] COC ; Contraception ; Estradiol ; Nomegestrol acetate ; Progestin
[en] SUMMARY : A new combined oral contraceptive called Zoely® has just been marketed in Belgium. It contains nomegestrol acetate, a progestin known for its high contraceptive reliability based on its antigonadotropic power and long half-life. This progestin is associated with estradiol and Zoely® is devoid of ethinyl estradiol, which is the usual component of the majority of combined oral contraceptives and is primarily responsible for thrombotic side effects of the pill. The compositon and type of regimen of this new oral contraceptive contribute to its efficacy and excellent clinical tolerance.

File(s) associated to this reference

Fulltext file(s):

Open access
PINTIAUX ZOELY 2012.pdfPublisher postprint109.9 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.